QRG Capital Management Inc. Purchases 6,011 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

QRG Capital Management Inc. increased its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 84.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,139 shares of the company’s stock after purchasing an additional 6,011 shares during the quarter. QRG Capital Management Inc.’s holdings in GE HealthCare Technologies were worth $1,027,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. D1 Capital Partners L.P. purchased a new position in shares of GE HealthCare Technologies in the 3rd quarter worth approximately $268,159,000. Van ECK Associates Corp lifted its holdings in GE HealthCare Technologies by 107.3% during the fourth quarter. Van ECK Associates Corp now owns 4,841,652 shares of the company’s stock worth $378,520,000 after acquiring an additional 2,506,417 shares during the period. State Street Corp boosted its position in GE HealthCare Technologies by 7.8% in the third quarter. State Street Corp now owns 18,615,890 shares of the company’s stock worth $1,747,101,000 after purchasing an additional 1,347,114 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in GE HealthCare Technologies in the 3rd quarter valued at $93,713,000. Finally, Jennison Associates LLC increased its position in shares of GE HealthCare Technologies by 124.5% during the 4th quarter. Jennison Associates LLC now owns 1,709,635 shares of the company’s stock valued at $133,659,000 after purchasing an additional 948,017 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on GEHC. Wells Fargo & Company boosted their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Citigroup boosted their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price target for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $97.67.

GE HealthCare Technologies Trading Down 1.0 %

NASDAQ:GEHC opened at $86.45 on Tuesday. GE HealthCare Technologies Inc. has a 1 year low of $74.51 and a 1 year high of $94.80. The stock’s fifty day moving average price is $86.31 and its two-hundred day moving average price is $86.14. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The company has a market cap of $39.53 billion, a P/E ratio of 19.97, a P/E/G ratio of 3.19 and a beta of 1.15.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The business had revenue of $5.32 billion for the quarter, compared to analysts’ expectations of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. As a group, analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.